MaxCyte starts dosing second cohort of patients in earlystage trial of its lead cancer drug

MaxCyte starts dosing second cohort of patients in early-stage trial of its lead cancer drug

03:25 EDT 8 May 2019 | Proactive Investors

There were no safety concerns from the first set of patients enrolled into the trial, so MaxCyte is to up the dose for those in the second cohort as planned

More From BioPortfolio on "MaxCyte starts dosing second cohort of patients in early-stage trial of its lead cancer drug"